01:47 , Feb 15, 2019 |  BC Week In Review  |  Company News

IBM, Broad to use AI to improve CV genetic risk prediction

The Broad Institute of MIT and Harvard and the IBM Watson Health business of IBM Corp. (NYSE:IBM) have teamed up to develop artificial intelligence algorithms to improve the predictive power of polygenic scoring of cardiovascular...
21:15 , Feb 13, 2019 |  BC Extra  |  Company News

IBM, Broad to use AI to improve CV genetic risk prediction

The Broad Institute of MIT and Harvard and the IBM Watson Health business of IBM Corp. (NYSE:IBM) have teamed up to develop artificial intelligence algorithms to improve the predictive power of polygenic scoring of cardiovascular...
05:09 , Jan 5, 2019 |  BioCentury  |  Product Development

Bristol-Myers’ next phoenix act?

Bristol-Myers Squibb Co. will now be in the driver’s seat to monetize the assets gained from the myriad deals Celgene Corp. has forged. The pharma will need to mimic its history of using well-timed acquisitions...
00:50 , Jan 5, 2019 |  BC Extra  |  Company News

Flurry of management moves on eve of JPM

More than 30 biopharma companies announced executive changes to kick off the New Year, including Ironwood Pharmaceuticals Inc. (NASDAQ:IRWD) and Immunocore Ltd. (Abingdon, U.K.), both of which brought on former AstraZeneca plc (LSE:AZN; NYSE:AZN) executives...
01:15 , Dec 22, 2018 |  BioCentury  |  Product Development

A year of digital progress at Novartis

Novartis AG Chief Digital Officer Bertrand Bodson is capping off his inaugural year with the pharma’s first approval of a digital therapeutic and 10 deals under his belt to integrate new technologies throughout the company....
01:21 , Dec 8, 2018 |  BioCentury  |  Strategy

Novo gets serious about AI-guided drug design

Novo Nordisk A/S is fashioning its R&D makeover to integrate artificial intelligence across its drug discovery and development process, after a pilot program delivered the cost and time savings the pharma was looking for. In...
16:10 , Nov 16, 2018 |  BC Week In Review  |  Company News

U.K. Supreme Court deals Pfizer setback in Lyrica case

A U.K. Supreme Court decision will likely make it more difficult for branded drugmakers to protect the exclusivity of their products within related indications with its Nov. 14 decision that invalidated second medical use patent...
23:32 , Nov 14, 2018 |  BC Extra  |  Company News

U.K. Supreme Court deals Pfizer setback in Lyrica case

A U.K. Supreme Court decision will likely make it more difficult for branded drugmakers to protect the exclusivity of their products within related indications with its Wednesday decision that invalidated second medical use patent claims...
18:13 , Aug 31, 2018 |  BC Week In Review  |  Financial News

ApoGen expands series A to $11M

Drug-resistant cancer company ApoGen Biotechnologies Inc. raised an additional $4 million on Aug. 23 from M Ventures and existing investors in its series A round, bringing the round's total to $11 million. M Ventures is...
21:53 , Aug 17, 2018 |  BioCentury  |  Finance

MD Anderson’s blooms

The recent launch of Magnolia Neurosciences Corp. with a $31 million series A round is the latest example of a broader effort by the University of Texas MD Anderson Cancer Center to ramp up company...